Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)
NCT00004845 · View on ClinicalTrials.gov ↗
Study Summary
The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
Conditions Studied
Interventions
- DRUG Naproxen
- DRUG Rofecoxib
Study Locations (20)
Florida
- Baumel-Eisner Neuromedical Institute, Boca Raton — Boca Raton
- Baumel-Eisner Ft Lauderdale — Fort Lauderdale
- Mayo Clinic Jacksonville — Jacksonville
- Wein Center — Miami Beach
- Baumel-Eisner Neuromedical Institute, MiamiBeach — Miami Beach
- University of South Florida — Tampa
- Premiere Research Institute — West Palm Beach
California
- University of California Irvine Institute for Brain Aging and Dementia — Irvine
- University of California, San Diego — La Jolla
- University of Southern California — Los Angeles
- University of California, Los Angeles — Los Angeles
- University of California, Davis — Martinez
Arizona
- Barrow Neurological Group — Phoenix
- University of Arizona, Tucson — Tucson
Connecticut
- Yale University, School of Medicine — New Haven
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Georgia
- Emory University — Atlanta
Illinois
- Rush Presbyterian St. Luke's Medical Center — Chicago
Indiana
- Indiana University Medical Center — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004845
The ClinicalTrials.gov registry entry for NCT00004845 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Aging (NIA), which has 127 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions — of which Naproxen is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00004845 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00004845 about?
NCT00004845 is a clinical study titled "A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)". The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
What is the current status of trial NCT00004845?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2001-12.
What conditions does trial NCT00004845 study?
This clinical trial studies the following conditions: Alzheimer Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00004845?
The interventions under investigation include: Naproxen (DRUG), Rofecoxib (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00004845?
This trial is sponsored by National Institute on Aging (NIA), which has 127 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00004845 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.